Alnylam Pharmaceuticals, Inc. (ALNY)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
AMVUTTRA Revenue	2.89B	2.31B	970.45M
AMVUTTRA Revenue Growth	25.06%	138.43%	73.97%
ONPATTRO Revenue	143.78M	172.79M	252.86M
ONPATTRO Revenue Growth	-16.79%	-31.66%	-28.68%
GIVLAARI Revenue	315.91M	308.49M	255.87M
GIVLAARI Revenue Growth	2.41%	20.56%	16.70%
OXLUMO Revenue	200.67M	191.44M	167.05M
OXLUMO Revenue Growth	4.82%	14.60%	52.09%
Total Product Revenue	3.55B	2.99B	1.65B
Total Product Revenue Growth	19.00%	81.42%	32.60%
Roche - Collaboration Revenue	413.47M	394.88M	119.49M
Roche - Collaboration Revenue Growth	4.71%	230.47%	-64.63%
Regeneron Pharmaceuticals - Collaboration Revenue	109.25M	113.96M	302.80M
Regeneron Pharmaceuticals - Collaboration Revenue Growth	-4.13%	-62.37%	201.39%
Novartis AG - Collaboration Revenue	-	-	79.76M
Novartis AG - Collaboration Revenue Growth	-	-	-8.03%
Other - Collaboration Revenue (Post-FY2022)	13.54M	44.53M	8.18M
Other - Collaboration Revenue (Post-FY2022) Growth	-69.60%	444.69%	-61.42%
Total Collaboration Revenue	536.26M	553.37M	510.22M
Total Collaboration Revenue Growth	-3.09%	8.46%	-6.59%
Royalty Revenue	196.53M	174.02M	91.79M
Royalty Revenue Growth	12.93%	89.58%	125.91%
Revenue (Other)	-536.26M	-553.36M	-510.23M
Revenue (Total)	4.29B	3.71B	2.25B
Revenue (Total) Growth	15.43%	65.19%	22.97%

Updated Apr 30, 2026. Data Source: Fiscal.ai.